CJC-1295 (no DAC) (5 mg)
CJC-1295 No DAC (Modified GRF 1-29) is a tetrasubstituted 29-amino acid GHRH analogue (D-Ala2, Gln8, Ala15, Leu27) engineered for DPP-4 enzymatic resistance and pulsatile somatotroph receptor signaling (~30 min half-life).
Scientific Profile & Research Key Points: CJC-1295 (no DAC)
CJC-1295 No DAC (Modified GRF 1-29) is a tetrasubstituted 29-amino acid GHRH analogue (D-Ala2, Gln8, Ala15, Leu27) engineered for DPP-4 enzymatic resistance and pulsatile somatotroph receptor signaling (~30 min half-life).
Active Batch Release Specifications (Lot SL-2026-116)
Analytical release verification for current CJC-1295 (no DAC) (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-116 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (1.0–2.0 mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate reconstituted solution at 2°C–8°C for up to 28 days.
CJC-1295 (no DAC) — Technical Questions & Answers
What is the molar concentration when reconstituting CJC-1295 (no DAC) (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of CJC-1295 (no DAC) (MW 3367.97 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 0.74 mM (742 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does CJC-1295 (no DAC)'s counterion stoichiometry affect assay mass calculations?
CJC-1295 (no DAC) (CAS 863288-34-0, formula C152H252N44O42) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify CJC-1295 (no DAC) Lot SL-2026-116 and what pathway does it target?
Lot SL-2026-116 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 3367.97 g/mol. In preclinical literature, CJC-1295 (no DAC) targets Pituitary GHRH Receptor (Class B GPCR) (Jetté L. et al., Endocrinology (2005) — Tetrasubstituted GHRH(1-29) resistance to DPP-4 enzymatic cleavage (PMID: 15817669)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
CJC-1295, Ipamorelin, and Sermorelin: GHRH Analogues vs Ghrelin Receptor Agonists
A deep dive into somatotropic axis stimulation. Comparing GHRH receptor binding, DAC modification kinetics, ghrelin/GHS-R1a agonism, and pulsatile growth hormone secretion.
Gonadorelin, HCG, HMG and Kisspeptin: Mapping the Hypothalamic-Pituitary-Gonadal Axis
A comparative map of the HPG axis: GnRH receptor agonism (Gonadorelin), LH receptor mimetics (HCG), combined FSH/LH activity (HMG), and upstream GPR54 activation (Kisspeptin-10).
Human Growth Hormone (191aa): Somatropin Structure, Isoforms, and SEC-HPLC Analysis
A deep analysis of authentic 191-amino acid Somatropin vs 192-amino acid Somatrem. Size-exclusion chromatography (SEC), deamidation artifacts, and mass confirmation.
Related GH Secretagogues & Growth Factors Compounds
View category →